WAM
SAGE

Wolverine Asset Management’s Sage Therapeutics SAGE Stock Holding History

Wolverine Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,233
Closed -$126K – 2300
2021
Q2 		$126K Buy
+2,233
New +$158K ﹤0.01% 1402
2021
Q1 		– Sell
-16
Closed -$1K – 2242
2020
Q4 		$1K Buy
+16
New +$1.18K ﹤0.01% 1603
2020
Q3 		– Sell
-1,631
Closed -$67K – 1754
2020
Q2 		$67K Buy
+1,631
New +$59.2K ﹤0.01% 1177

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Wolverine Asset Management's SAGE Position: Q3 2021 in Review

Wolverine Asset Management sold out of Sage Therapeutics (SAGE) in Q3 2021, closing a stake of 2,233 shares — an estimated $126K sold.

Wolverine Asset Management first reported a position in SAGE in Q2 2020 and held it in 3 quarters. The position peaked at $126K in Q2 2021. 226 funds tracked by Wall St. Rank hold SAGE as of Q3 2021.

  • Wolverine Asset Management reported no remaining Sage Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Wolverine Asset Management sold 2,233 Sage Therapeutics shares in Q3 2021, an estimated $126K.
  • Wolverine Asset Management first reported a position in Sage Therapeutics in Q2 2020 and held it in 3 quarters.
  • Wolverine Asset Management's Sage Therapeutics position peaked at $126K in Q2 2021.
  • 226 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2021.

Based on Wolverine Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.